Bladder Carcinoma clinical trials

Explore recruiting bladder carcinoma clinical trials.

Recruiting bladder carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Bladder Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible for cisplatin-based chemotherapy. (PeRioperative Immunotherapy combined with Sacituzumab govitecan in Muscle invasive blAdder cancer)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Intravesical instillation therapy with bacillus Calmette-Guérin (BCG) and sequential BCG and electromotive mitomycin-C (EMDA-MMC) in patients with high-risk non-muscle-invasive bladder carcinoma (FINNBLADDER 10)

Finland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b/2, dose expansion, open-label study to evaluate safety and anti-tumor activity of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer.

Spain, Romania

Phase I and Phase II (Integrated)- Other EU CTIS Study details

BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology

Hungary

Therapeutic use (Phase IV) EU CTIS Study details

Bladder Carcinoma trials by city

Bladder Carcinoma in Toronto Bladder Carcinoma in Vancouver Bladder Carcinoma in Montreal Bladder Carcinoma in Calgary Bladder Carcinoma in Edmonton Bladder Carcinoma in Ottawa Bladder Carcinoma in Winnipeg Bladder Carcinoma in Quebec City Bladder Carcinoma in Hamilton Bladder Carcinoma in Kitchener Bladder Carcinoma in London Bladder Carcinoma in Halifax Bladder Carcinoma in New York Bladder Carcinoma in Los Angeles Bladder Carcinoma in Chicago Bladder Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease